Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 631 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stage IIIB Non-small Cell Lung Cancer Clear all
Completed Phase 2 Interventional Results available

Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00227539
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, pemetrexed disodium, adjuvant therapy, therapeutic conventional surgery, fludeoxyglucose F 18
Drug · Procedure · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 4, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer

NCT00653939
View directory record Official record
Conditions
Tumors
Interventions
Fosbretabulin, Carboplatin, Paclitaxel, Bevacizumab
Drug
Lead sponsor
Mateon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
15
States / cities
Campbell, California • Fountain Valley, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Oct 4, 2026, 1:28 AM EDT
Not listed Phase 2 Interventional

Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

NCT00083083
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, docetaxel, etoposide, paclitaxel, vinblastine sulfate, vinorelbine tartrate, gene expression analysis, positron emission tomography, fludeoxyglucose F 18, radiation therapy
Drug · Genetic · Procedure + 1 more
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
46
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 4, 2026, 1:28 AM EDT
Completed Phase 2 Interventional

Docetaxel and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00003762
View directory record Official record
Conditions
Lung Cancer
Interventions
docetaxel, gemcitabine hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
17
States / cities
Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 4, 2026, 1:28 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00601094
View directory record Official record
Conditions
Lung Cancer
Interventions
autologous dendritic cell-adenovirus CCL21 vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 4, 2026, 1:28 AM EDT
Recruiting Phase 3 Interventional

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Sotorasib, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
29
States / cities
Santa Barbara, California • Newark, Delaware • Coral Springs, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 4, 2026, 1:28 AM EDT
Terminated Phase 2 Interventional Results available

Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer

NCT00460551
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Zalutumumab, Induction chemotherapy, Radiotherapy
Biological · Drug · Radiation
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Towson, Maryland • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 4, 2026, 1:28 AM EDT
Terminated Phase 2 Interventional Results available

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.

NCT00773383
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
RG1507, erlotinib [Tarceva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Santa Monica, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 4, 2026, 1:28 AM EDT
Completed Phase 1 Interventional

Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer

NCT01958372
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
soy isoflavones, cisplatin, etoposide, pemetrexed disodium, radiation therapy
Dietary Supplement · Drug · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
5
States / cities
Bay City, Michigan • Detroit, Michigan • Lapeer, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 4, 2026, 1:28 AM EDT
Terminated Phase 1 Interventional

A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer

NCT01574222
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
autologous dendritic cell adenovirus CCL21 vaccine
Biological
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 4, 2026, 1:28 AM EDT
Completed Phase 3 Interventional

Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer

NCT01999673
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Stage IV, Non-Small-Cell Lung Cancer Metastatic, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Nonsmall Cell Lung Cancer
Interventions
bavituximab, Docetaxel, Placebo (for bavituximab)
Biological · Drug · Other
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
39
States / cities
Huntsville, Alabama • Chandler, Arizona • Glendale, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 4, 2026, 1:28 AM EDT
Terminated Phase 3 Interventional Results available

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

NCT03447769
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
21
States / cities
Fayetteville, Arkansas • Los Alamitos, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 4, 2026, 1:28 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00091663
View directory record Official record
Conditions
Lung Cancer, Non-small-cell Lung Carcinoma
Interventions
Tarceva (erlotinib HCl)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
92
States / cities
Huntsville, Alabama • Anchorage, Alaska • Glendale, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 4, 2026, 1:28 AM EDT
Completed Phase 1 Interventional

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

NCT00045006
View directory record Official record
Conditions
Cancer
Interventions
vorinostat
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 4, 2026, 1:28 AM EDT
Not listed Phase 2 Interventional

Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00003562
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, docetaxel
Drug
Lead sponsor
Hope Cancer Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
2
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 4, 2026, 1:28 AM EDT
Completed Phase 2 Interventional

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

NCT01496742
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Placebo, RO5490258, bevacizumab [Avastin], cisplatin/carboplatin, paclitaxel, pemetrexed
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
32
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 4, 2026, 1:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00023673
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, three-dimensional conformal radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
40
States / cities
Mobile, Alabama • Phoenix, Arizona • Burbank, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 4, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Results available

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

NCT00413283
View directory record Official record
Conditions
Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer, Lung Neoplasms, Oncology, Solid Tumors, Thrombocytopenia
Interventions
Romiplostim, Placebo, Gemcitabine, Carboplatin, Cisplatin
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
51
States / cities
Glendale, Arizona • Anaheim, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 4, 2026, 1:28 AM EDT
Completed Phase 1 Interventional

Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer

NCT01457469
View directory record Official record
Conditions
Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Tobacco Use Disorder
Interventions
questionnaire administration, quality-of-life assessment, counseling intervention, internet-based intervention, telephone-based intervention, educational intervention, nicotine replacement therapy
Other · Procedure · Behavioral + 1 more
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 4, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Results available

Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer

NCT01507428
View directory record Official record
Conditions
Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
18F-Fluoromisonidazole, Carboplatin, Computed Tomography, External Beam Radiation Therapy, Fludeoxyglucose F-18, Image-Guided Adaptive Radiation Therapy, Laboratory Biomarker Analysis, Paclitaxel, Positron Emission Tomography
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
29
States / cities
Palo Alto, California • Augusta, Georgia • Chicago, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 4, 2026, 1:28 AM EDT
Active, not recruiting Phase 1 Interventional

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

NCT05334329
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Antineoplastic Immune Cell, Atezolizumab, Biospecimen Collection, Cyclophosphamide, Fludarabine
Biological · Procedure · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 4, 2026, 1:28 AM EDT
Completed Phase 1 Interventional

Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00734890
View directory record Official record
Conditions
Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bevacizumab, vandetanib, laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 4, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Results available

Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00124618
View directory record Official record
Conditions
Lung Cancer
Interventions
cetuximab, radiation therapy
Biological · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
175
States / cities
Scottsdale, Arizona • Hollywood, Florida • Jacksonville, Florida + 107 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 4, 2026, 1:28 AM EDT
Terminated Phase 1 Interventional

A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma

NCT02298153
View directory record Official record
Conditions
NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer)
Interventions
Epacadostat, Atezolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 4, 2026, 1:28 AM EDT